Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, Garcia-Gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia-What to look for when treatment-free remission is not an option. Blood Rev. 2022;56:100968.

Article  CAS  PubMed  Google Scholar 

Franklin BA, Eijsvogels TMH, Pandey A, Quindry J, Toth PP. Physical activity, cardiorespiratory fitness, and cardiovascular health: a clinical practice statement of the ASPC part I: bioenergetics, contemporary physical activity recommendations, benefits, risks, extreme exercise regimens, potential maladaptations. Am J Prev Cardiol. 2022;12:100424.

Article  PubMed  PubMed Central  Google Scholar 

Lando J, Nicole MAB, Meggie MCMD, Esmée AB, Malou AHN, Jeroen JWMJ, et al. Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity. Haematologica 2020;106:1876–82.

Article  Google Scholar 

Janssen L, Hopman MTE, Swaans GJA, Allard NAE, Boss M, Lobeek D, et al. Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in chronic myeloid leukemia patients. Am J Physiol Endocrinol Metab. 2023;324:E209–16.

Everett BM, Brooks MM, Vlachos HEA, Chaitman BR, Frye RL, Bhatt DL. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med. 2015;373:610–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eggers KM, Jernberg T, Lindahl B. Cardiac troponin elevation in patients without a specific diagnosis. J Am Coll Cardiol. 2019;73:1–9.

Article  CAS  PubMed  Google Scholar 

Aengevaeren VL, Hopman MTE, Thompson PD, Bakker EA, George KP, Thijssen DHJ, et al. Exercise-induced cardiac troponin I increase and incident mortality and cardiovascular events. Circulation. 2019;140:804–14.

Article  PubMed  Google Scholar 

Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908–16.

Article  PubMed  Google Scholar 

Atallah E, Cortes J, O’Brien S, Pierce S, Rios MB, Estey E, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007;110:3547–51.

Article  CAS  PubMed  Google Scholar 

Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer. 2007;43:974–8.

Article  CAS  PubMed  Google Scholar 

Bouitbir J, Panajatovic MV, Krähenbühl S. Mitochondrial toxicity associated with imatinib and sorafenib in isolated rat heart fibers and the cardiomyoblast H9c2 cell line. Int J Mol Sci. 2022;23:2282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aengevaeren VL, Baggish AL, Chung EH, George K, Kleiven Ø, Mingels AMA, et al. Exercise-induced cardiac troponin elevations: from underlying mechanisms to clinical relevance. Circulation. 2021;144:1955–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gordon JK, Magid SK, Maki RG, Fleisher M, Berman E. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res. 2010;34:827–9.

Article  CAS  PubMed  Google Scholar 

Janssen L, Frambach S, Allard NAE, Hopman MTE, Schirris TJJ, Voermans NC, et al. Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Leukemia. 2019;33:2116–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109:282–7.

Article  CAS  PubMed  Google Scholar 

Brancaccio P, Lippi G, Maffulli N. Biochemical markers of muscular damage. Clin Chem Lab Med. 2010;48:757–67.

Article  CAS  PubMed  Google Scholar